Novan Announces Promising Clinical Results with SB414

MORRISVILLE, N.C., Aug. 20, 2018 (GLOBE NEWSWIRE) — Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced an update on the SB414 nitric oxide-releasing cream product candidate and its application to two therapeutic indications: atopic dermatitis and psoriasis. Based on results of two complementary Phase 1b clinical trials with SB414 in patients with psoriasis and atopic dermatitis, Novan intends to advance the development of SB414 as a treatment for atopic dermatitis and conduct additional exploratory trials in psoriasis and acne rosacea.